Zymeworks: Hold Rating Maintained Amid Financial Improvements and Early-Stage Growth Potential

Analyst Robert Burns of H.C. Wainwright reiterated a Hold rating on Zymeworks (ZYME – Research Report), retaining the price target of $13.00.

Robert Burns has given his Hold rating due to a combination of factors influencing Zymeworks’ current financial and developmental outlook. The company’s recent financial results for the first quarter of 2025 showed a narrower net loss per share than previously anticipated, indicating some positive financial management. However, despite this improvement, the projected net loss for the full year remains significant, and the company’s cash reserves are expected to support operations only into the second half of 2027.
Additionally, Zymeworks has presented promising preclinical data for several of its early-stage assets, which could potentially lead to future growth. Yet, these developments are still in early phases, with key regulatory and clinical milestones expected in the coming years. Given these factors, including the current share price and the uncertain timeline for these potential catalysts, Burns maintains a Neutral stance with a 12-month price target of $13.

Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ZYME in relation to earlier this year.